- Home
- OLP vs PHAR Comparison
OLP vs PHAR Comparison
Compare OLP & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- PHAR
- Stock Information
- Founded
- OLP 1982
- PHAR 1988
- Country
- OLP United States
- PHAR Netherlands
- Employees
- OLP N/A
- PHAR N/A
- Industry
- OLP Real Estate Investment Trusts
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- OLP Real Estate
- PHAR Health Care
- Exchange
- OLP Nasdaq
- PHAR Nasdaq
- Market Cap
- OLP 569.9M
- PHAR 731.1M
- IPO Year
- OLP N/A
- PHAR N/A
- Fundamental
- Price
- OLP $24.27
- PHAR $10.31
- Analyst Decision
- OLP Strong Buy
- PHAR Strong Buy
- Analyst Count
- OLP 1
- PHAR 3
- Target Price
- OLP $28.00
- PHAR $30.00
- AVG Volume (30 Days)
- OLP 78.9K
- PHAR 3.6K
- Earning Date
- OLP 08-05-2025
- PHAR 07-31-2025
- Dividend Yield
- OLP 7.46%
- PHAR N/A
- EPS Growth
- OLP N/A
- PHAR N/A
- EPS
- OLP 1.35
- PHAR N/A
- Revenue
- OLP $92,152,000.00
- PHAR $320,708,000.00
- Revenue This Year
- OLP $11.87
- PHAR $13.31
- Revenue Next Year
- OLP $4.72
- PHAR $7.68
- P/E Ratio
- OLP $17.91
- PHAR N/A
- Revenue Growth
- OLP 3.31
- PHAR 24.13
- 52 Week Low
- OLP $22.32
- PHAR $6.65
- 52 Week High
- OLP $30.45
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- OLP 48.30
- PHAR 43.60
- Support Level
- OLP $23.79
- PHAR $9.99
- Resistance Level
- OLP $24.32
- PHAR $10.49
- Average True Range (ATR)
- OLP 0.49
- PHAR 0.34
- MACD
- OLP -0.02
- PHAR -0.14
- Stochastic Oscillator
- OLP 36.86
- PHAR 7.45
About OLP One Liberty Properties Inc.
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.